177 related articles for article (PubMed ID: 36209277)
1. Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma.
Topham JT; Tsang ES; Karasinska JM; Metcalfe A; Ali H; Kalloger SE; Csizmok V; Williamson LM; Titmuss E; Nielsen K; Negri GL; Spencer Miko SE; Jang GH; Denroche RE; Wong HL; O'Kane GM; Moore RA; Mungall AJ; Loree JM; Notta F; Wilson JM; Bathe OF; Tang PA; Goodwin R; Morin GB; Knox JJ; Gallinger S; Laskin J; Marra MA; Jones SJM; Schaeffer DF; Renouf DJ
Nat Commun; 2022 Oct; 13(1):5941. PubMed ID: 36209277
[TBL] [Abstract][Full Text] [Related]
2. Correlation between KRAS gene mutations and linicopathological features of patients with intrahepatic cholangiocarcinoma.
Wang J; Xu MX; Wang LQ; Li HY; Wang ZL; Li LJ
J Biol Regul Homeost Agents; 2019; 33(5):1551-1557. PubMed ID: 31635679
[No Abstract] [Full Text] [Related]
3. Annexin A10 optimally differentiates between intrahepatic cholangiocarcinoma and hepatic metastases of pancreatic ductal adenocarcinoma: a comparative study of immunohistochemical markers and panels.
Kälsch J; Padden J; Bertram S; Pott LL; Reis H; Westerwick D; Schaefer CM; Sowa JP; Möllmann D; Fingas C; Dechȇne A; Sitek B; Eisenacher M; Canbay A; Ahrens M; Baba HA
Virchows Arch; 2017 May; 470(5):537-543. PubMed ID: 28357490
[TBL] [Abstract][Full Text] [Related]
4. Recurrent Rearrangements in PRKACA and PRKACB in Intraductal Oncocytic Papillary Neoplasms of the Pancreas and Bile Duct.
Singhi AD; Wood LD; Parks E; Torbenson MS; Felsenstein M; Hruban RH; Nikiforova MN; Wald AI; Kaya C; Nikiforov YE; Favazza L; He J; McGrath K; Fasanella KE; Brand RE; Lennon AM; Furlan A; Dasyam AK; Zureikat AH; Zeh HJ; Lee K; Bartlett DL; Slivka A
Gastroenterology; 2020 Feb; 158(3):573-582.e2. PubMed ID: 31678302
[TBL] [Abstract][Full Text] [Related]
5. Mutation analysis and copy number changes of KRAS and BRAF genes in Taiwanese cases of biliary tract cholangiocarcinoma.
Huang WC; Tsai CC; Chan CC
J Formos Med Assoc; 2017 Jun; 116(6):464-468. PubMed ID: 27745798
[TBL] [Abstract][Full Text] [Related]
6. A special subtype: Revealing the potential intervention and great value of KRAS wildtype pancreatic cancer.
Xu ZH; Wang WQ; Liu L; Lou WH
Biochim Biophys Acta Rev Cancer; 2022 Jul; 1877(4):188751. PubMed ID: 35732240
[TBL] [Abstract][Full Text] [Related]
7. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.
Philip PA; Azar I; Xiu J; Hall MJ; Hendifar AE; Lou E; Hwang JJ; Gong J; Feldman R; Ellis M; Stafford P; Spetzler D; Khushman MM; Sohal D; Lockhart AC; Weinberg BA; El-Deiry WS; Marshall J; Shields AF; Korn WM
Clin Cancer Res; 2022 Jun; 28(12):2704-2714. PubMed ID: 35302596
[TBL] [Abstract][Full Text] [Related]
8. Hilar cholangiocarcinoma and pancreatic ductal adenocarcinoma share similar histopathologies, immunophenotypes, and development-related molecules.
Gandou C; Harada K; Sato Y; Igarashi S; Sasaki M; Ikeda H; Nakanuma Y
Hum Pathol; 2013 May; 44(5):811-21. PubMed ID: 23134772
[TBL] [Abstract][Full Text] [Related]
9. [Prognosis after resection of intrahepatic cholangiocarcinoma: clinical significance of KRAS mutations].
Schneider MA; Büchler MW
Chirurg; 2022 Mar; 93(3):306-307. PubMed ID: 35175401
[No Abstract] [Full Text] [Related]
10. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
11. Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
Boerner T; Drill E; Pak LM; Nguyen B; Sigel CS; Doussot A; Shin P; Goldman DA; Gonen M; Allen PJ; Balachandran VP; Cercek A; Harding J; Solit DB; Schultz N; Kundra R; Walch H; D'Angelica MI; DeMatteo RP; Drebin J; Kemeny NE; Kingham TP; Simpson AL; Hechtman JF; Vakiani E; Lowery MA; Ijzermans JNM; Buettner S; Koerkamp BG; Doukas M; Chandwani R; Jarnagin WR
Hepatology; 2021 Sep; 74(3):1429-1444. PubMed ID: 33765338
[TBL] [Abstract][Full Text] [Related]
12. Intratumor Heterogeneity of KRAS Mutation Status in Pancreatic Ductal Adenocarcinoma Is Associated With Smaller Lesions.
Nagawkar SS; Abu-Funni S; Simon E; Bick T; Prinz E; Sabo E; Ben-Izhak O; Hershkovitz D
Pancreas; 2016 Jul; 45(6):876-81. PubMed ID: 26646269
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of KRAS Mutations in Pancreatic Ductal Adenocarcinoma.
Hashimoto D; Arima K; Yokoyama N; Chikamoto A; Taki K; Inoue R; Kaida T; Higashi T; Nitta H; Ohmuraya M; Hirota M; Beppu T; Baba H
Pancreas; 2016 Sep; 45(8):1111-4. PubMed ID: 26967456
[TBL] [Abstract][Full Text] [Related]
14. Utility of KRAS mutational analysis in the preoperative diagnosis of synchronous pancreatic cancer and intrahepatic cholangiocarcinoma: A case report.
Eso Y; Uza N; Yamagishi H; Imada K; Kimura Y; Masui T; Kodama Y; Seno H
Medicine (Baltimore); 2017 Dec; 96(50):e9217. PubMed ID: 29390348
[TBL] [Abstract][Full Text] [Related]
15. Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma.
Choi MH; Mejlænder-Andersen E; Manueldas S; El Jellas K; Steine SJ; Tjensvoll K; Sætran HA; Knappskog S; Hoem D; Nordgård O; Hovland R; Molven A
BMC Cancer; 2019 Jan; 19(1):11. PubMed ID: 30611220
[TBL] [Abstract][Full Text] [Related]
16. MDM2 Amplification in Intrahepatic Cholangiocarcinomas: Its Relationship With Large-Duct Type Morphology and Uncommon KRAS Mutations.
Kim SJ; Akita M; Sung YN; Fujikura K; Lee JH; Hwang S; Yu E; Otani K; Hong SM; Zen Y
Am J Surg Pathol; 2018 Apr; 42(4):512-521. PubMed ID: 29309301
[TBL] [Abstract][Full Text] [Related]
17. KRAS mutation in intrahepatic cholangiocarcinoma: Linkage with metastasis-free survival and reduced E-cadherin expression.
Tanaka M; Kunita A; Yamagishi M; Katoh H; Ishikawa S; Yamamoto H; Abe J; Arita J; Hasegawa K; Shibata T; Ushiku T
Liver Int; 2022 Oct; 42(10):2329-2340. PubMed ID: 35833881
[TBL] [Abstract][Full Text] [Related]
18. FNA smears of pancreatic ductal adenocarcinoma are superior to formalin-fixed paraffin-embedded tissue as a source of DNA: Comparison of targeted KRAS amplification and genotyping in matched preresection and postresection samples.
Hartley CP; Mahajan AM; Selvaggi SM; Rehrauer WM
Cancer Cytopathol; 2017 Nov; 125(11):838-847. PubMed ID: 29024530
[TBL] [Abstract][Full Text] [Related]
19. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
20. Significance of KRAS mutation testing in biliary brushing cytology specimens: A 10-year retrospective review.
Sun T; Zuo T; Hui P; Cai G
Cancer Cytopathol; 2022 Jul; 130(7):558-565. PubMed ID: 35417072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]